Adverse events recorded in the 2 groups
| Adverse events, n (%) . | RTX + rhTPO (n = 77) . | RTX (n = 38) . |
|---|---|---|
| Fever | 19 (24.7) | 8 (21.0%) |
| Upper respiratory infection | 12 (15.6) | 5 (13.2) |
| Urinary tract infection | 5 (6.5) | 2 (5.3) |
| Gastrointestinal infections | 3 (3.9) | 1 (2.6) |
| Muscle/joint pain* | 3 (3.9) | 2 (5.3) |
| Insomnia | 4 (5.2) | 2 (5.3) |
| Stomachache | 0 | 1 (2.6) |
| Headache | 0 | 1 (2.6) |
| Chest congestion | 0 | 1 (2.6) |
| Rash* | 0 | 2 (5.3) |
| Malaise | 1 (1.3) | 0 |
| Thrombosis | 1 (1.3) | 0 |
| Encephalorrhagia | 1 (1.3) | 0 |
| Anti-thrombopoietin antibody | 2 (2.6) | 0 |
| Adverse events, n (%) . | RTX + rhTPO (n = 77) . | RTX (n = 38) . |
|---|---|---|
| Fever | 19 (24.7) | 8 (21.0%) |
| Upper respiratory infection | 12 (15.6) | 5 (13.2) |
| Urinary tract infection | 5 (6.5) | 2 (5.3) |
| Gastrointestinal infections | 3 (3.9) | 1 (2.6) |
| Muscle/joint pain* | 3 (3.9) | 2 (5.3) |
| Insomnia | 4 (5.2) | 2 (5.3) |
| Stomachache | 0 | 1 (2.6) |
| Headache | 0 | 1 (2.6) |
| Chest congestion | 0 | 1 (2.6) |
| Rash* | 0 | 2 (5.3) |
| Malaise | 1 (1.3) | 0 |
| Thrombosis | 1 (1.3) | 0 |
| Encephalorrhagia | 1 (1.3) | 0 |
| Anti-thrombopoietin antibody | 2 (2.6) | 0 |
These 2 adverse events were considered to be serum sickness.